63843-81-2

Basic information

• Product Name: 5-BROMO-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE
• Synonyms: 5-BROMO-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE;5-bromo-3-indolylglyoxalyl chloride;1H-INDOLE-3-ACETYL CHLORIDE, 5-BROMO-α-OXO-;2-(5-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
• CAS NO: 63843-81-2
• Molecular Formula: C₁₀H₅BrClNO₂
• Molecular Weight: 286.51
• Mol File: 63843-81-2.mol
• Article Data: 41

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BROMO-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(63843-81-2)
• EPA Substance Registry System: 5-BROMO-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(63843-81-2)

Safety Data

• Hazardous Substances Data: 63843-81-2(Hazardous Substances Data)

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 1201646-31-2 3-(4-methoxybenzyl)-8-(pyridin-3-yl)-3H-pyrazolo[3,4-c]quinolin-4(5H)-one 
• 1201646-32-3 4-chloro-3-(4-methoxybenzyl)-8-(pyridin-3-yl)-3H-pyrazolo[3,4-c]quinoline 
• 1201646-33-4 3-(4-methoxybenzyl)-8-(pyridin-3-yl)-3H-pyrazolo[3,4-c]quinoline 
• 1201646-30-1 8-bromo-3-(4-methoxybenzyl)-3H-pyrazolo[3,4-c]quinolin-4(5H)-one 
• 208464-79-3 C₂₆H₂₈N₂O₂ 
• 208464-52-2 5-(1-hydroxycyclohex-1-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-61-3 5-(cyclohex-1-en-1-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-69-1 5-Cyclohexyl-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-44-2 5-bromo-3-(2-pyrrolidinylethyl)-1-benzoylindole 
• 208464-62-4 5-(1-aza-1-benzylcyclohex-3-en-4-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 174021-63-7 tert-butyl N-[2-(5-bromo-1H-indol-3-yl)ethyl]carbamate 

Relevant articles and documents

Synthesis and preliminary biological evaluation of indol-3-yl-oxoacetamides as potent cannabinoid receptor type 2 ligands

A small series of indol-3-yl-oxoacetamides was synthesized starting from the literature known N-(adamantan-1-yl)-2-(5-(furan-2-yl)-1-pentyl-1H-indol-3-yl)-2-oxoacetamide (5) by substituting the 1-pentyl-1H-indole subunit. Our preliminary biological evaluation showed that the fluorinated derivative 8 is a potent and selective CB2 ligand with Ki = 6.2 nM.

3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation

A series of 3-(7-azainodyl)-4-indolylmaleimides was designed, synthesized, and evaluated for their isocitrate dehydrogenase 1 (IDH1)/R132H inhibitory activities. Many compounds such as 11a, 11c, 11e, 11g, and 11s exhibited favorable inhibitory effects on IDH1/R132H and were highly selective against the wild-type IDH1. Evaluation of the biological activities at the cellular level showed that compounds 11a, 11c, 11e, 11g, and 11s could effectively suppress the production of 2-hydroxyglutaric acid in U87MG cells expressing IDH1/R132H. Preliminary structure–activity relationship (SAR) and molecular modeling studies were discussed based on the experimental data obtained. These findings may provide new insights into the development of novel IDH1/R132H inhibitors.

Development of [18F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging

Dysregulation of glycogen synthase kinase-3β (GSK-3β) is implicated in the pathogenesis of neurodegenerative and psychiatric disorders. Thus, development of GSK-3β radiotracers for positron emission tomography (PET) imaging is of paramount importance, because such a noninvasive imaging technique would allow better understanding of the link between the activity of GSK-3β and central nervous system disorders in living organisms, and it would enable early detection of the enzyme’s aberrant activity. Herein, we report the synthesis and biological evaluation of a series of fluorine-substituted maleimide derivatives that are high-affinity GSK-3β inhibitors. Radiosynthesis of a potential GSK-3β tracer [18F]10a is achieved. Preliminary in vivo PET imaging studies in rodents show moderate brain uptake, although no saturable binding was observed in the brain. Further refinement of the lead scaffold to develop potent [18F]-labeled GSK-3 radiotracers for PET imaging of the central nervous system is warranted.